



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0188-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Yves JACOB et al.) Group Art Unit: 1645
Application No.: 10/608,538)
Examiner: Unassigned
Filed: June 30, 2003)
For: CHIMERIC LYSSAVIRUS) Confirmation No.: 8265
NUCLEIC ACIDS AND)
POLYPEPTIDES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced.

Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

With respect to the non-English language document, Applicants submit the following remarks:

1. EP 0 696 191 B1 - An abstract of the disclosure of this document can be found in the English language Derwent Abstract submitted herewith.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


Dated: May 11, 2004

By: 

Deborah Katz
Reg. No. 51,863
Phone: 202.408.4382
Fax: 202.408.4400
E-mail: deborah.katz@finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03495.0188-01	Appln. No.	10/608,538
Applicant	Yves JACOB et al.		
Filing Date	June 30, 2003	Group:	1645



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	6,673,601	January 6, 2004	Jacob et al.			
	Appl. No. 09/958,672		Jacob et al.			International Filing Date: April 17, 2000

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 90 11092	10/1990	PCT			
	WO 93 06223	04/1993	PCT			Abstract
	WO 95/09249	04/1995	PCT			
	EPO 696 191 B1	10/1994	EPO			Abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Amengual, B. et al., "Evolution of European Bat Lyssaviruses", <i>J. Gen. Virol.</i> , 78 :2319-2328 (1997).
	Bahloul, C. et al., "DNA-based Immunization for Exploring the Enlargement of Immunological Cross-reactivity Against the Lyssaviruses", <i>Vaccine</i> , 16 :417-425 (1998).
	Benmansour et al., "Antigenicity of Rabies Virus Glycoprotein", <i>J. Virol.</i> , 65 (8):4198-4203 (1991).
	Buffett et al., "P. Falciparum Domain Mediating Adhesion to Chondroitin Sulfate A: A Receptor for Human Placental Infection", <i>PNAS</i> , 96 (22):12743-48 (1999).
	Coulon et al., "An Avirulent Mutant of Rabies Virus is Unable to Infect Motoneurons <i>In Vivo</i> and <i>In Vitro</i> ", <i>J. Virol.</i> , 72 (1):273-278 (1998).
	Desmézières et al.; Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines; <i>J. Gen. Virol.</i> (1999), 80 :2343-2351
	Dietzschold et al., "Structural and Immunological Characterization of a Linear Virus-Neutralizing Epitope of the Rabies Virus Glycoprotein and its Possible Use in a Synthetic Vaccine", <i>Vaccine</i> , 64 (8):3804-3809 (1990).
	Donnelly, J. et al., "DNA Vaccines", <i>Annu. Rev. Immunol.</i> , 15 :617-648 (1997).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	03495.0188-01	Appln. No.	10/608,538
Applicant	Yves JACOB et al.		
Filing Date	June 30, 2003	Group:	1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Editorial, Vaccine, Vol. 14, pp. 579-732 (1996).
	Ertl., et al., "Novel Vaccine Approaches", <i>Journal of Immunology</i> , 156 :3579-3582 (1996).
	European Commission COST/STD-3, "Advantages of Combined Vaccines", <i>Vaccine</i> , 14 (7):693-700 (1996).
	Gaudin, Y., et al., "Reversible Conformational Changes and Fusion Activity of Rabies Virus Glycoprotein", <i>J. Virol.</i> , 65 (9):4853-4859 (1991).
	Gaudin, Y. et al., "Biological Function of the Low-pH, Fusion-inactive Conformation of Rabies Virus Glycoprotein (G): G is Transported in a Fusion-inactive State-like Conformation", <i>J. Virol.</i> , 69 (9):5528-5533 (1995).
	Gaudin, Y., "Folding of Rabies Virus Glycoprotein: Epitope Acquisition and Interaction with Endoplasmic reticulum Chaperones", <i>J. Virol.</i> , 71 (15):3742-3750 (1997).
	Jallet et al., "Chimeric Lyssavirus Glycoproteins with Increased Immunological Potential", <i>Journal of Virology</i> , 73 (1):225-233 (1999).
	Lafay et al., "Immunodominant Epitopes Defined by a Yeast-expressed Library of Random Fragments of the Rabies Virus Glycoprotein Map Outside Major Antigenic Sites", <i>J. Gen. Virol.</i> , B77 :339-346 (1996).
	Lafon et al., "Antigenic Sites on the CVS Rabies Virus Glycoprotein: Analysis with Monoclonal Antibodies", <i>J. Gen. Virol.</i> , 64 :843-845 (1983).
	Lafon, M. et al., "Use of a monoclonal Antibody for Quantitation of Rabies Vaccine Glycoprotein by Enzyme Immunoassay", <i>J. Biol. Standard</i> , 13 :295-301 (1985).
	Lang, J. et al., "Randomised Feasibility Trial of Pre-Exposure Rabies Vaccination with DTP-IPV in Infants", <i>The Lancet</i> , 349 :1663-1665 (1997).
	Liu et al., "Polynucleotide Vaccines: A Potential New Generation of Vaccines," <i>Proc. Eur. Assoc. Vet. Pharmacol. Toxicol. 6 Meet.</i> , 301, Abstract Only (1994).
	Lodmell, D. et al., "DNA Immunization Protects Nonhuman Primates Against Rabies Virus", <i>Nature Med.</i> , 4 (8):949-952 (1998a).
	Lodmell, D. et al., "Gene Gun Particle-Mediated Vaccination with Plasmid DNA Confers Protective Immunity Against Rabies Virus Infection", <i>Vaccine</i> , 16 (2/3):115-118 (1998b).
	MacFarlan, R. et al., "T Cell Responses to Cleaved Rabies Glycoprotein and to Synthetic Peptides", <i>J. Immunol.</i> , 133 (5):2748-2752 (1984).
	Macy et al., <i>Vet. Clin. North Am small Anim. Pract.</i> , Abstract Only, 26 (1):103-109 (1996).
	Mebatsion et al., "Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles", <i>Journal of Virology</i> , 69 (3):1444-1451 (1995).
	Paoletti et al., <i>PNAS</i> , 93 (21):11349-53 (1996).

INFORMATION DISCLOSURE CITATION

Atty. Docket No. 03495.0188-01	Appln. No. 10/608,538
Applicant Yves JACOB et al.	
Filing Date June 30, 2003	Group: 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Pastoret, P-P. et al., "Vaccination Against Rabies", <i>In Veterinary Vaccinology</i> , Pastoret, Eds. (Elsevier):616-628 (1997). s
	Perrin, P. et al., "Rabies Immunosome (Subunit Vaccine) Structure and Immunogenicity", <i>Vaccine</i> , 3:325-332 (1985).
	Perrin, P. et al., "The Influence of the Type of Immunosorbent on Rabies Antibody EIA: Advantages of Purified Glycoprotein over Whole Virus", <i>J. Biol. Standard</i> , 14:95-102 (1986).
	Perrin, P. et al. Interleukin 2 increases protection against experimental rabies, <i>Immunobiology</i> , vol. 177, pp. 199-209 (1988).
	Perrin, P. "Techniques for the Preparation of Rabies Conjugates", <i>In Laboratory Techniques in Rabies</i> , 4 th Ed. (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:433-445 (1996a).
	Perrin, P. et al., "The Antigen-Specific Cell-Mediated Immune Response in Mice is Suppressed by Infection with Pathogenic Lyssaviruses", <i>Res. Virol.</i> , 147:289-299 (1996b).
	Rogers, S., et al., Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis, <i>Science</i> , vol. 234, pp. 364-369 (1986).
	Smith, J. et al., "A Rapid Fluorescent Focus Inhibition Test (RFFIT) for Determining Virus-Neutralizing Antibody", <i>In Laboratory Techniques in Rabies</i> , 4 th Ed. (Eds Meslin, F-X; Kaplan, M. and Koprowski, H.) WHO, Geneva:181-189 (1996).
	Thomson, S. et al., "Delivery of Multiple CD8 Cytotoxic Cell Epitopes by DNA Vaccination", <i>J. Immunol.</i> , 160(4):1717-1723 (1998).
	Tine et al., "NYVAC-Pf7: A Poxvirus-vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium Falciparum Malaria," <i>Infection and Immunity</i> , 64(9):3833-3844 (1996).
	Tuffereau et al., "Neuronal Cell Surface Molecules Mediate Specific Binding to Rabies Virus Glycoprotein Expressed by a Recombinant Baculovirus on the Surfaces of Lepidopteran Cells", <i>J. Virol.</i> , 72(2):1085-1091 (1998).
	Wunner, W. et al., "Localization of Immunogenic Domains on the Rabies Virus Glycoprotein," <i>Ann. Inst. Pasteur</i> , 136E:353-362 (1985).
	Xiang, Z. et al., "Vaccination with a Plasmid Vector Carrying the Rabies Virus Glycoprotein Gene Induces Protective Immunity Against rabies Virus", <i>Virol.</i> , 199:132-140 (1994).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce